IP Library Granted Patent US 8,980,864
Granted Patent B2
US 8,980,864 · App. 14/135,887 · Granted Mar 17, 2015

Compositions and methods of altering cholesterol levels

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,980,864
App. No.
14/135,887
Granted
Mar 17, 2015
Kind
B2
Abstract

The present invention relates to compositions, methods and kits using polynucleotides, primary transcripts and mmRNA molecules.

Claims (5)

1. A method of reducing serum levels of cholesterol in a subject comprising administering to said subject a modified mRNA encoding a LDLR mutant, said modified mRNA comprising at least one nucleoside modification, wherein said at least one nucleoside modification is 1-methylpseudouridine and wherein said modified mRNA encodes a protein identical to SEQ ID NO: 19 except for one or more substitution mutations that change the identity of one or more amino acids at one or more of positions 316-339 of SEQ ID NO: 19 in combination with an mRNA encoding a CYP7A1 protein, said mRNA comprising the base sequence of SEQ ID NO: 39 except that each thymidine is replaced by a uridine.

2. The method of claim 1 , wherein the modified mRNA encoding a LDLR mutant encodes a protein selected from the group consisting of SEQ ID NOs: 33-38.

3. The method of claim 2 , where the protein encoded by the modified mRNA encoding a LDLR mutant comprises four amino acid mutations.

4. The method of claim 1 , wherein the region of said modified mRNA encoding the LDLR mutant is codon-optimized.

5. The method of claim 1 , wherein the mRNA encoding the CYP7A1 protein comprises at least one nucleoside modification, wherein said at least one nucleoside modification is 1-methylpseudouridine.

Assignments (3)
SECURITY INTEREST Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
CHANGE OF NAME Recorded Oct 4, 2016
From: MODERNA THERAPEUTICS, INC
To: MODERNATX, INC.
Reel/Frame 040220/0194 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2014
From: HOGE, STEPHEN G.; DE FOUGEROLLES, ANTONIN; ELLSWORTH, JEFF LYNN
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032492/0709 →